共 768 条
[1]
Vogelstein B(2004)Cancer genes and the pathways they control Nat Med 10 789-799
[2]
Kinzler KW(2011)Hallmarks of cancer: the next generation Cell. 144 646-674
[3]
Hanahan D(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science. 304 1497-1500
[4]
Weinberg RA(2007)Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561-566
[5]
Paez JG(2008)A mouse model for EML4-ALK-positive lung cancer Proc Natl Acad Sci U S A 105 19893-19897
[6]
Jänne PA(2019)Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy Nat Rev Cancer 19 495-509
[7]
Lee JC(2019)Co-mutations in EGFR driven non-small cell lung cancer EBioMedicine. 42 18-19
[8]
Tracy S(2018)Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer Ann Oncol 29 2068-2075
[9]
Greulich H(2019)Targeting oncogenic drivers in lung cancer: recent progress, current challenges and future opportunities Pharmacol Ther 193 20-30
[10]
Gabriel S(2018)Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology J Mol Diagn 20 129-159